{"id":54307,"date":"2023-05-16T19:28:20","date_gmt":"2023-05-16T19:28:20","guid":{"rendered":"https:\/\/cdhf.staging.not4prod.com\/?p=54307"},"modified":"2026-04-21T14:42:37","modified_gmt":"2026-04-21T14:42:37","slug":"newfoundland-and-labrador-biosimilars-policy","status":"publish","type":"post","link":"https:\/\/cdhf.ca\/en\/newfoundland-and-labrador-biosimilars-policy\/","title":{"rendered":"Newfoundland and Labrador Biosimilars Policy"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong><strong>What is Changing in the Newfoundland and Labrador Coverage for Biologics?<\/strong><\/strong><\/p>\n\n\n\n<p class=\"arrow-link wp-block-paragraph\"><a href=\"https:\/\/www.gov.nl.ca\/hcs\/prescription\/biosimilars\/\">View the Newfoundland Labrador Biosimilars Website <\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The Government of Newfoundland and Labrador is expanding the use of biosimilar drug treatments offered through the Newfoundland and Labrador Prescription Drug Program. Under this initiative, to maintain coverage, patients with <a href=\"https:\/\/cdhf.ca\/en\/digestive-conditions\/ibd-crohns-disease\/\">inflammatory Bowel Disease (IBD)<\/a> currently using one of the originator biologics of&nbsp;<strong>Humira\u00ae, and Remicade\u00ae<\/strong>&nbsp;will be transitioned to a safe, effective and less costly biosimilar version on or before March 31, 2024.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This initiative follows similar efforts elsewhere in Canada including Alberta, Quebec, New Brunswick, Northwest Territories, and Ontario. Tens of thousands of Canadians have safely switched to a biosimilar in those initiatives. They are also used extensively in Europe, where countries have had over 15 years of experience with biosimilars.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Program beneficiaries who have been identified as using one or more of these originator biologics will receive a letter which contains additional information, as well as outlining the next steps needed to transition to a biosimilar. The Newfoundland and Labrador Prescription Drug Program will continue to work with partners, including health professionals and manufacturers, to ensure a successful transition.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For information on the Biosimilars Initiative, please visit the Newfoundland and Labrador Prescription Drug Program&nbsp;<a href=\"http:\/\/www.gov.nl.ca\/hcs\/prescription\/biosimilars\">website<\/a>. <\/p>\n\n\n\n<figure class=\"wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe title=\"Newfoundland and Labrador Biosimilars Policy for IBD Patients\" width=\"500\" height=\"281\" src=\"https:\/\/www.youtube.com\/embed\/0c4AQlA4m1g?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Biologic Medications Included in the NLPDP Biosimilars Initiative:<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">When more than one biosimilar option exists for an originator, it is the patient\u2019s choice, in consultation with their health professional, which biosimilar option they will use. Additional originator biologics will be added to the initiative as new biosimilar options are approved by Health Canada and listed as benefits of NLPDP.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table><tbody><tr><td><strong>Biologic*<\/strong><\/td><td><strong>Originator Biologic*<\/strong><\/td><td><strong>Funded Biosimilar(s)*<\/strong><\/td><td><strong>Originator coverage&nbsp;<\/strong><strong>end date<\/strong><\/td><\/tr><tr><td colspan=\"4\"><\/td><\/tr><tr><td><strong>adalimumab<\/strong><\/td><td><strong>Humira<\/strong><\/td><td><strong>Abrilada, Amgevita, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, Yuflyma<\/strong><\/td><td><strong>April 1, 2024<\/strong><\/td><\/tr><tr><td>enoxaparin<\/td><td>Lovenox<\/td><td>Inclunox, Noromby, Redesca, Elonox<\/td><td>April 1, 2024<\/td><\/tr><tr><td>etanercept<\/td><td>Enbrel<\/td><td>Brenzys, Erelzi<\/td><td>April 1, 2024<\/td><\/tr><tr><td>glatiramer<\/td><td>Copaxone<\/td><td>Glatect<\/td><td>April 1, 2024<\/td><\/tr><tr><td><strong>infliximab<\/strong><\/td><td><strong>Remicade<\/strong><\/td><td><strong>Avsola, Inflectra, Renflexis<\/strong><\/td><td><strong>April 1, 2024<\/strong><\/td><\/tr><tr><td>rituximab<\/td><td>Rituxan<\/td><td>Riximyo, Ruxience, Truxima<\/td><td>April 1, 2024<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>CDHF Biosimilar Library<\/strong><\/h2>\n\n\n\n<p class=\"arrow-link wp-block-paragraph\"><a href=\"https:\/\/cdhf.ca\/en\/biosimilar-library\/\">Learn More about Biosimilars and What they are at our Biosimilar Library<\/a> <\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"frequently-asked-questions\"><strong>Frequently Asked Questions<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>1. What is a biologic?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Biologic (reference) drugs are medications made by using living organisms (such as yeast or animal cells) to produce complex proteins that are purified then administered to affect certain processes in the human body.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>2. What is a biosimilar?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A biosimilar is a drug demonstrated to be highly similar to a biologic (reference) drug, that has been authorized for sale in Canada.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">3. What is the NLPDP Biosimilar Initiative?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">NLPDP Biosimilar Initiative is a biosimilars transition policy where beneficiaries using<br>certain originator biologics will transition to a biosimilar version to maintain coverage.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>4. How do I get my prescription changed to a biosimilar<\/strong>? Do I need a new special authorization?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">If you have Inflammatory Bowel Disease, and currently use <strong>Humira\u00ae, or Remicade\u00ae<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Your prescriber can assist you with transitioning to a biosimilar no later than your next special authorization reassessment and renewal appointment<\/li>\n\n\n\n<li>Your next special authorization will be approved for a biosimilar<\/li>\n\n\n\n<li>Your prescriber can help answer your questions, explain the transition process and write your biosimilar prescription If you are not due to see your prescriber on or before March 31, 2024, You will need to make an appointment to discuss transitioning your medication to a biosimilar and having a new special authorization and prescription completed<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>5. Why is the change happening?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The Newfoundland and Labrador Prescription Drug Program Biosimilars Initiative provides an evidence-based opportunity to get the best value from medications funded under the program, without negatively affecting patient health outcomes. This will allow the program to invest in new and innovative drug therapies while continuing to expand access to existing drug treatments.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>6. Are biosimilars safe and effective compared to the originator biologic drug?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Yes, before a biosimilar drug is approved by Health Canada, the manufacturer must show that there are no meaningful differences in safety and effectiveness compared to the originator version. Patients should expect no difference when transitioning from an originator biologic to its biosimilar version.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"resourcelinks\"><strong>CDHF Resource Links<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/cdhf.ca\/en\/biosimilar-library\/\">Explore CDHF\u2019s Biosimilar Library<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/cdhf.ca\/en\/cdhf-talks-your-new-infusion-clinic\/\">CDHFTalks: Your New Infusion Clinic.. Not the Same, but Similar.<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/cdhf.ca\/wp-content\/uploads\/2022\/08\/CDHF-EnglishBiosimilarTransitionPathwayBrochure.pdf\">CDHF | Transition Pathway Brochure for IBD Patients<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/cdhf.ca\/biosimilars-for-ibd-making-the-transition\/\">CDHF | Biosimilars for IBD: Making the Transition Webinar<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/cdhf.ca\/en\/whats-health-canada-saying-about-biosimilars-animation\/\">CDHF | What\u2019s Health Canada saying about Biosimilars Animation<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/cdhf.ca\/en\/whats-health-canada-saying-about-biosimilars-infographic\/\">CDHF | What\u2019s Health Canada saying about Biosimilars Infographic<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/cdhf.ca\/switching-from-a-biologic-to-a-biosimilar\/\">CDHF | IBD: Switching from a Biologic to a Biosimilar Animation<\/a><\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Other Relevant Resources<\/strong><\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/biosimilaroptions.ca\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Biosimilars Working Group<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/crohnsandcolitis.ca\/\" target=\"_blank\" rel=\"noreferrer noopener\">Crohn\u2019s and <\/a><a href=\"https:\/\/crohnsandcolitis.ca\/Get-Involved\/Advocating-for-change\/Non-Medical-Switch-Biosimilars\">Colitis Canada<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/biosim.jointhealth.org\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Biosim Exchange<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/biosimilar_drugs_professional_en.pdf\">CADTH Biosimilar Drugs | Fact Sheet<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/biosimilar_drugs_professional_en.pdf\">Health Canada, Biosimilar Biologic Drugs in Canada | Fact Sheet<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/biologics-radiopharmaceuticals-genetic-therapies\/applications-submissions\/guidance-documents\/information-submission-requirements-biosimilar-biologic-drugs-1.html\">Government of Canada | Guidance Documents: Information and Submission Requirements for Biosimilar Biologic Drug<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>What is Changing in the Newfoundland and Labrador Coverage for Biologics? View the Newfoundland Labrador Biosimilars Website The Government of Newfoundland and Labrador is expanding the use of biosimilar drug treatments offered through the Newfoundland and Labrador Prescription Drug Program. Under this initiative, to maintain coverage, patients with inflammatory Bowel Disease (IBD) currently using one [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":54310,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"cdhf2022_sponsors_meta":[],"footnotes":""},"categories":[60],"tags":[85],"class_list":["post-54307","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-article","tag-biologics-biosimilars"],"acf":{"article_writer":[101]},"featured_image_src":"https:\/\/cdhf.ca\/wp-content\/uploads\/2023\/05\/honneur-11.webp","author_info":{"display_name":"Kelsey Cheyne","author_link":"https:\/\/cdhf.ca\/en\/author\/kelsey-cheyne\/"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.1.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Newfoundland and Labrador Biosimilars Policy - Canadian Digestive Health Foundation<\/title>\n<meta name=\"description\" content=\"Newfoundland and Labrador is expanding the use of biosimilar drug treatments offered called the newfoundland and labrador biosimilar policy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cdhf.ca\/en\/newfoundland-and-labrador-biosimilars-policy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Newfoundland and Labrador Biosimilars Policy - Canadian Digestive Health Foundation\" \/>\n<meta property=\"og:description\" content=\"Newfoundland and Labrador is expanding the use of biosimilar drug treatments offered called the newfoundland and labrador biosimilar policy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cdhf.ca\/en\/newfoundland-and-labrador-biosimilars-policy\/\" \/>\n<meta property=\"og:site_name\" content=\"Canadian Digestive Health Foundation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/CDHFdn\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-16T19:28:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-21T14:42:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cdhf.ca\/wp-content\/uploads\/2023\/05\/honneur-11.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"2000\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Kelsey Cheyne\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@TheCDHF\" \/>\n<meta name=\"twitter:site\" content=\"@TheCDHF\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Kelsey Cheyne\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cdhf.ca\/en\/newfoundland-and-labrador-biosimilars-policy\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/cdhf.ca\/en\/newfoundland-and-labrador-biosimilars-policy\/\"},\"author\":{\"name\":\"Kelsey Cheyne\",\"@id\":\"https:\/\/cdhf.ca\/en\/#\/schema\/person\/990293ff50f898caf38644b75a0105aa\"},\"headline\":\"Newfoundland and Labrador Biosimilars Policy\",\"datePublished\":\"2023-05-16T19:28:20+00:00\",\"dateModified\":\"2026-04-21T14:42:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cdhf.ca\/en\/newfoundland-and-labrador-biosimilars-policy\/\"},\"wordCount\":763,\"publisher\":{\"@id\":\"https:\/\/cdhf.ca\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/cdhf.ca\/en\/newfoundland-and-labrador-biosimilars-policy\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cdhf.ca\/wp-content\/uploads\/2023\/05\/honneur-11.webp\",\"keywords\":[\"Biologics &amp; Biosimilars\"],\"articleSection\":[\"Article\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cdhf.ca\/en\/newfoundland-and-labrador-biosimilars-policy\/\",\"url\":\"https:\/\/cdhf.ca\/en\/newfoundland-and-labrador-biosimilars-policy\/\",\"name\":\"Newfoundland and Labrador Biosimilars Policy - Canadian Digestive Health Foundation\",\"isPartOf\":{\"@id\":\"https:\/\/cdhf.ca\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cdhf.ca\/en\/newfoundland-and-labrador-biosimilars-policy\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cdhf.ca\/en\/newfoundland-and-labrador-biosimilars-policy\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cdhf.ca\/wp-content\/uploads\/2023\/05\/honneur-11.webp\",\"datePublished\":\"2023-05-16T19:28:20+00:00\",\"dateModified\":\"2026-04-21T14:42:37+00:00\",\"description\":\"Newfoundland and Labrador is expanding the use of biosimilar drug treatments offered called the newfoundland and labrador biosimilar policy.\",\"breadcrumb\":{\"@id\":\"https:\/\/cdhf.ca\/en\/newfoundland-and-labrador-biosimilars-policy\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cdhf.ca\/en\/newfoundland-and-labrador-biosimilars-policy\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cdhf.ca\/en\/newfoundland-and-labrador-biosimilars-policy\/#primaryimage\",\"url\":\"https:\/\/cdhf.ca\/wp-content\/uploads\/2023\/05\/honneur-11.webp\",\"contentUrl\":\"https:\/\/cdhf.ca\/wp-content\/uploads\/2023\/05\/honneur-11.webp\",\"width\":2000,\"height\":900,\"caption\":\"newfoundland\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cdhf.ca\/en\/newfoundland-and-labrador-biosimilars-policy\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cdhf.ca\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Newfoundland and Labrador Biosimilars Policy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cdhf.ca\/en\/#website\",\"url\":\"https:\/\/cdhf.ca\/en\/\",\"name\":\"Canadian Digestive Health Foundation\",\"description\":\"Serving Canadians with the latest digestive health news &amp; information\",\"publisher\":{\"@id\":\"https:\/\/cdhf.ca\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cdhf.ca\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cdhf.ca\/en\/#organization\",\"name\":\"Canadian Digestive Health Foundation\",\"url\":\"https:\/\/cdhf.ca\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cdhf.ca\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cdhf.ca\/wp-content\/uploads\/2022\/07\/CDHF_logo_sqstck_4line_CMYK.png\",\"contentUrl\":\"https:\/\/cdhf.ca\/wp-content\/uploads\/2022\/07\/CDHF_logo_sqstck_4line_CMYK.png\",\"width\":1154,\"height\":554,\"caption\":\"Canadian Digestive Health Foundation\"},\"image\":{\"@id\":\"https:\/\/cdhf.ca\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/CDHFdn\",\"https:\/\/x.com\/TheCDHF\",\"https:\/\/www.instagram.com\/cdhf_\/?hl=en\",\"https:\/\/www.youtube.com\/user\/CDHFtube\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cdhf.ca\/en\/#\/schema\/person\/990293ff50f898caf38644b75a0105aa\",\"name\":\"Kelsey Cheyne\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Newfoundland and Labrador Biosimilars Policy - Canadian Digestive Health Foundation","description":"Newfoundland and Labrador is expanding the use of biosimilar drug treatments offered called the newfoundland and labrador biosimilar policy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cdhf.ca\/en\/newfoundland-and-labrador-biosimilars-policy\/","og_locale":"en_US","og_type":"article","og_title":"Newfoundland and Labrador Biosimilars Policy - Canadian Digestive Health Foundation","og_description":"Newfoundland and Labrador is expanding the use of biosimilar drug treatments offered called the newfoundland and labrador biosimilar policy.","og_url":"https:\/\/cdhf.ca\/en\/newfoundland-and-labrador-biosimilars-policy\/","og_site_name":"Canadian Digestive Health Foundation","article_publisher":"https:\/\/www.facebook.com\/CDHFdn","article_published_time":"2023-05-16T19:28:20+00:00","article_modified_time":"2026-04-21T14:42:37+00:00","og_image":[{"width":2000,"height":900,"url":"https:\/\/cdhf.ca\/wp-content\/uploads\/2023\/05\/honneur-11.webp","type":"image\/png"}],"author":"Kelsey Cheyne","twitter_card":"summary_large_image","twitter_creator":"@TheCDHF","twitter_site":"@TheCDHF","twitter_misc":{"Written by":"Kelsey Cheyne","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cdhf.ca\/en\/newfoundland-and-labrador-biosimilars-policy\/#article","isPartOf":{"@id":"https:\/\/cdhf.ca\/en\/newfoundland-and-labrador-biosimilars-policy\/"},"author":{"name":"Kelsey Cheyne","@id":"https:\/\/cdhf.ca\/en\/#\/schema\/person\/990293ff50f898caf38644b75a0105aa"},"headline":"Newfoundland and Labrador Biosimilars Policy","datePublished":"2023-05-16T19:28:20+00:00","dateModified":"2026-04-21T14:42:37+00:00","mainEntityOfPage":{"@id":"https:\/\/cdhf.ca\/en\/newfoundland-and-labrador-biosimilars-policy\/"},"wordCount":763,"publisher":{"@id":"https:\/\/cdhf.ca\/en\/#organization"},"image":{"@id":"https:\/\/cdhf.ca\/en\/newfoundland-and-labrador-biosimilars-policy\/#primaryimage"},"thumbnailUrl":"https:\/\/cdhf.ca\/wp-content\/uploads\/2023\/05\/honneur-11.webp","keywords":["Biologics &amp; Biosimilars"],"articleSection":["Article"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/cdhf.ca\/en\/newfoundland-and-labrador-biosimilars-policy\/","url":"https:\/\/cdhf.ca\/en\/newfoundland-and-labrador-biosimilars-policy\/","name":"Newfoundland and Labrador Biosimilars Policy - Canadian Digestive Health Foundation","isPartOf":{"@id":"https:\/\/cdhf.ca\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cdhf.ca\/en\/newfoundland-and-labrador-biosimilars-policy\/#primaryimage"},"image":{"@id":"https:\/\/cdhf.ca\/en\/newfoundland-and-labrador-biosimilars-policy\/#primaryimage"},"thumbnailUrl":"https:\/\/cdhf.ca\/wp-content\/uploads\/2023\/05\/honneur-11.webp","datePublished":"2023-05-16T19:28:20+00:00","dateModified":"2026-04-21T14:42:37+00:00","description":"Newfoundland and Labrador is expanding the use of biosimilar drug treatments offered called the newfoundland and labrador biosimilar policy.","breadcrumb":{"@id":"https:\/\/cdhf.ca\/en\/newfoundland-and-labrador-biosimilars-policy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cdhf.ca\/en\/newfoundland-and-labrador-biosimilars-policy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cdhf.ca\/en\/newfoundland-and-labrador-biosimilars-policy\/#primaryimage","url":"https:\/\/cdhf.ca\/wp-content\/uploads\/2023\/05\/honneur-11.webp","contentUrl":"https:\/\/cdhf.ca\/wp-content\/uploads\/2023\/05\/honneur-11.webp","width":2000,"height":900,"caption":"newfoundland"},{"@type":"BreadcrumbList","@id":"https:\/\/cdhf.ca\/en\/newfoundland-and-labrador-biosimilars-policy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cdhf.ca\/en\/"},{"@type":"ListItem","position":2,"name":"Newfoundland and Labrador Biosimilars Policy"}]},{"@type":"WebSite","@id":"https:\/\/cdhf.ca\/en\/#website","url":"https:\/\/cdhf.ca\/en\/","name":"Canadian Digestive Health Foundation","description":"Serving Canadians with the latest digestive health news &amp; information","publisher":{"@id":"https:\/\/cdhf.ca\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cdhf.ca\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cdhf.ca\/en\/#organization","name":"Canadian Digestive Health Foundation","url":"https:\/\/cdhf.ca\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cdhf.ca\/en\/#\/schema\/logo\/image\/","url":"https:\/\/cdhf.ca\/wp-content\/uploads\/2022\/07\/CDHF_logo_sqstck_4line_CMYK.png","contentUrl":"https:\/\/cdhf.ca\/wp-content\/uploads\/2022\/07\/CDHF_logo_sqstck_4line_CMYK.png","width":1154,"height":554,"caption":"Canadian Digestive Health Foundation"},"image":{"@id":"https:\/\/cdhf.ca\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/CDHFdn","https:\/\/x.com\/TheCDHF","https:\/\/www.instagram.com\/cdhf_\/?hl=en","https:\/\/www.youtube.com\/user\/CDHFtube"]},{"@type":"Person","@id":"https:\/\/cdhf.ca\/en\/#\/schema\/person\/990293ff50f898caf38644b75a0105aa","name":"Kelsey Cheyne"}]}},"_links":{"self":[{"href":"https:\/\/cdhf.ca\/en\/wp-json\/wp\/v2\/posts\/54307","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cdhf.ca\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cdhf.ca\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cdhf.ca\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cdhf.ca\/en\/wp-json\/wp\/v2\/comments?post=54307"}],"version-history":[{"count":0,"href":"https:\/\/cdhf.ca\/en\/wp-json\/wp\/v2\/posts\/54307\/revisions"}],"acf:post":[{"embeddable":true,"href":"https:\/\/cdhf.ca\/en\/wp-json\/wp\/v2\/cdhf-writers\/101"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cdhf.ca\/en\/wp-json\/wp\/v2\/media\/54310"}],"wp:attachment":[{"href":"https:\/\/cdhf.ca\/en\/wp-json\/wp\/v2\/media?parent=54307"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cdhf.ca\/en\/wp-json\/wp\/v2\/categories?post=54307"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cdhf.ca\/en\/wp-json\/wp\/v2\/tags?post=54307"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}